Is the Pharma - API sector outperforming NIFTY 500?
The 52-week sector comparison is unavailable. 11 of 14 covered companies currently have positive Mansfield relative strength versus NIFTY 500.
20-quarter listed-company comparison
Pharma - API Stocks in India
Pharma - API: Aarti Drugs Ltd owns the largest revenue base; Ind-Swift Laboratories Ltd has the fastest current growth.
Nifty Pharma - API Index — Constituents & Performance
The Pharma - API companies below are the listed Indian Pharma - API universe this page tracks — the same constituent set people search for as the Nifty Pharma - API index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
The sector itself · before any single company
How has Pharma - API moved against NIFTY 500?
The line below covers 5.1 years. Over the most recent two of them this sector is 35% ahead of NIFTY 500. Earnings across its companies fell 16% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 17 weeks running.
LEADER · ahead 17w~Price up, without the fundamentals confirming10 of 13 companies ahead of NIFTY 500 by 5% or more over three months
RS ↑17w · 10/13 >200d (+0) · 10/13 lead (+0) · EPS 5/13↑
Pharma - API, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Strength anatomy
Broad but lateHow much of the sector is participating, how recently, and whether the movers score well.
Together10 of 13 stocks moving
Fresh1 crossed in the last 4 weeks
Backed by scoresmovers score +3 vs the sector average
Down the cap ladder — bar is now, tick is four weeks ago
Large
2/30
Mid
4/50
Small
4/50
Participation is not spreading downward this month; the larger companies are still carrying most of it.
Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 13 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
Sector relative strength · before individual stocks
Is Pharma - API outperforming NIFTY 500?
The 52-week comparison of Pharma - API against NIFTY 500 is not available from the current market series. 11 of 14 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Ind-Swift Laboratories Ltd is the strongest against the sector itself at +44.8%. Readings are as of 2026-07-19.
—Sector vs NIFTY 500 · 13 weeks
—Sector vs NIFTY 500 · 52 weeks
11/14Stocks leading NIFTY 500
5/14Stocks leading sector
Sector metric: 48.1 as of 2026-07-19 · NARROWING · rising.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
The 52-week sector comparison is unavailable. 11 of 14 covered companies currently have positive Mansfield relative strength versus NIFTY 500. Aarti Drugs Ltd leads with revenue of ₹2,566 crore, based on 14 of 14 comparable companies through Mar 2026. Ind-Swift Laboratories Ltd has the fastest current revenue growth at 100%, across 14 of 14 comparable companies.
Which Pharma - API company is largest by revenue?
Aarti Drugs Ltd leads with revenue of ₹2,566 crore, based on 14 of 14 comparable companies through Mar 2026.
Which Pharma - API company is growing fastest?
Ind-Swift Laboratories Ltd has the fastest current revenue growth at 100%, across 14 of 14 comparable companies.
Which Pharma - API company has the strongest 4-Factor Sector Score?
Senores Pharmaceuticals Ltd ranks first at 73.3/100 with 72% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Pharma - API company reports the most CAPEX?
Innova Captab Ltd reports the largest latest CAPEX at ₹121 crore, with 2 of 14 companies comparable.
Which Pharma - API company has the least gross debt?
Anuh Pharma Ltd has the lowest comparable gross debt at ₹0 crore. Aarti Pharmalabs Ltd has the highest at ₹754 crore.
Which Pharma - API company has the lowest comparable PEG?
Innova Captab Ltd has the lowest comparable Guarded PEG at 1.01, among 5 of 14 companies that pass the metric’s comparability rules.
How much history does this Pharma - API comparison include?
The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Companies
14
complete canonical membership
Combined market value
₹41.6K Cr
Senores Pharmaceuticals Ltd
Revenue growing
10/14
positive TTM year-on-year growth
Beating NIFTY 500
11/14
positive Mansfield relative strength
Global company selection
00 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Senores Pharmaceuticals Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 72% evidence confidence.
Fermenta Biotech Ltd has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is guarded: positive earnings, positive 5–60% three-year EPS growth, and a positive P/E are required.
1. Senores Pharmaceuticals Ltd · SENORES
73.3/100 · Favorable setup · 72% evidence
Exact sum: 30.8 + 15.2 + 9.2 + 18.1 = 73.3
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
30.8/35Growth & earnings
Revenue 62.3% · PAT 100% · OPM change 10 pp
83% evidence
15.2/25Capital efficiency
ROCE 15.1% · debt/equity 0.37×
80% evidence
9.2/20Valuation
P/E 55.4× · PEG —
15% evidence
18.1/20Relative strength
RS sector 28.8% · RS bench 60.8% · 1Y 125.1%
100% evidence
2. Wanbury Ltd · WANBURY
67.2/100 · Favorable setup · 73% evidence
Exact sum: 25.4 + 15.3 + 12.1 + 14.4 = 67.2
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25.4/35Growth & earnings
Revenue 16.5% · PAT 45.5% · OPM change 6 pp
71% evidence
15.3/25Capital efficiency
ROCE 36.6% · debt/equity 1.56×
95% evidence
12.1/20Valuation
P/E 27× · PEG —
50% evidence
14.4/20Relative strength
RS sector 5.3% · RS bench 29.2% · 1Y 23%
70% evidence
3. Innova Captab Ltd · INNOVACAP
62.6/100 · Mixed-positive evidence · 96% evidence
Exact sum: 22.1 + 15.3 + 14.5 + 10.7 = 62.6
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22.1/35Growth & earnings
Revenue 31.1% · PAT 10.2% · OPM change 0 pp
88% evidence
15.3/25Capital efficiency
ROCE 15% · debt/equity 0.32×
100% evidence
14.5/20Valuation
P/E 38.8× · PEG 1.01
100% evidence
10.7/20Relative strength
RS sector -4.7% · RS bench 19.4% · 1Y 6.8%
100% evidence
4. Ind-Swift Laboratories Ltd · INDSWFTLAB
59.0/100 · Mixed-positive evidence · 83% evidence
Exact sum: 22.3 + 10.4 + 6.3 + 20 = 59
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22.3/35Growth & earnings
Revenue 100% · PAT -80% · OPM change 19 pp
83% evidence
10.4/25Capital efficiency
ROCE 4.7% · debt/equity 0.01×
95% evidence
6.3/20Valuation
P/E 40× · PEG —
50% evidence
20.0/20Relative strength
RS sector 44.8% · RS bench 80.6% · 1Y 116.5%
100% evidence
5. Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM
58.3/100 · Mixed-positive evidence · 77% evidence
Exact sum: 16.8 + 19.1 + 10.6 + 11.8 = 58.3
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16.8/35Growth & earnings
Revenue 6.9% · PAT -22.2% · OPM change 2.5 pp
83% evidence
19.1/25Capital efficiency
ROCE 22.7% · debt/equity 0.03×
95% evidence
10.6/20Valuation
P/E 32.7× · PEG —
50% evidence
11.8/20Relative strength
RS sector 0.7% · RS bench 6.2% · 1Y -11.8%
70% evidence
6. Fermenta Biotech Ltd · FERMENTA
55.8/100 · Mixed-positive evidence · 70% evidence
Exact sum: 11.4 + 18 + 11.3 + 15.1 = 55.8
Decision use: Price leads the evidence: RS versus the benchmark is 30.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
11.4/35Growth & earnings
Revenue 11.9% · PAT -6.6% · OPM change -10 pp
83% evidence
18.0/25Capital efficiency
ROCE 20.6% · debt/equity 0.28×
95% evidence
11.3/20Valuation
P/E 20.2× · PEG —
15% evidence
15.1/20Relative strength
RS sector 15.7% · RS bench 30.6% · 1Y 16%
70% evidence
7. Aarti Drugs Ltd · AARTIDRUGS
50.3/100 · Mixed-positive evidence · 90% evidence
Exact sum: 17.5 + 12.4 + 13.3 + 7.1 = 50.3
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17.5/35Growth & earnings
Revenue 7.5% · PAT 16.1% · OPM change -1 pp
88% evidence
12.4/25Capital efficiency
ROCE 11.9% · debt/equity 0.37×
100% evidence
13.3/20Valuation
P/E 18.9× · PEG 2.4
100% evidence
7.1/20Relative strength
RS sector -10.7% · RS bench 0.1% · 1Y -19.3%
70% evidence
8. Anuh Pharma Ltd · ANUHPHR
50.3/100 · Mixed-positive evidence · 77% evidence
Exact sum: 16.7 + 14 + 13 + 6.6 = 50.3
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16.7/35Growth & earnings
Revenue 16.5% · PAT -12.8% · OPM change 1 pp
83% evidence
14.0/25Capital efficiency
ROCE 14.9% · debt/equity 0×
95% evidence
13.0/20Valuation
P/E 21.8× · PEG —
50% evidence
6.6/20Relative strength
RS sector -5.4% · RS bench -3.6% · 1Y -16.3%
70% evidence
9. Kopran Ltd · KOPRAN
44.0/100 · Mixed-negative evidence · 77% evidence
Exact sum: 16.9 + 11.2 + 8.1 + 7.8 = 44
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16.9/35Growth & earnings
Revenue 8.3% · PAT -34.2% · OPM change 4 pp
83% evidence
11.2/25Capital efficiency
ROCE 6.7% · debt/equity 0.29×
95% evidence
8.1/20Valuation
P/E 37.3× · PEG —
50% evidence
7.8/20Relative strength
RS sector -17.6% · RS bench 28.8% · 1Y 14.4%
70% evidence
10. Beta Drugs Ltd · BETA
43.0/100 · Mixed-negative evidence · 77% evidence
Exact sum: 11.5 + 15.9 + 7.4 + 8.2 = 43
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11.5/35Growth & earnings
Revenue -11.3% · PAT -14.8% · OPM change 2 pp
95% evidence
15.9/25Capital efficiency
ROCE 19.2% · debt/equity 0.6×
80% evidence
7.4/20Valuation
P/E 52.9× · PEG —
50% evidence
8.2/20Relative strength
RS sector -17.9% · RS bench 37.4% · 1Y 32.5%
70% evidence
11. Gujarat Themis Biosyn Ltd · GUJTHEM
38.2/100 · Mixed-negative evidence · 89% evidence
Exact sum: 15 + 15.7 + 6.4 + 1.1 = 38.2
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15.0/35Growth & earnings
Revenue 8.6% · PAT -6.1% · OPM change 2 pp
88% evidence
15.7/25Capital efficiency
ROCE 17.9% · debt/equity 0.56×
100% evidence
6.4/20Valuation
P/E 84.2× · PEG 2.77
65% evidence
1.1/20Relative strength
RS sector -21.8% · RS bench -1.6% · 1Y 0.7%
100% evidence
12. Themis Medicare Ltd · THEMISMED
33.6/100 · Adverse evidence · 68% evidence
Exact sum: 13 + 6.6 + 8.5 + 5.5 = 33.6
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13.0/35Growth & earnings
Revenue -15.6% · PAT -80% · OPM change 15.7 pp
62% evidence
6.6/25Capital efficiency
ROCE 2.7% · debt/equity 0.25×
95% evidence
8.5/20Valuation
P/E 613× · PEG —
15% evidence
5.5/20Relative strength
RS sector -15.7% · RS bench 5.8% · 1Y -12.6%
100% evidence
13. Aarti Pharmalabs Ltd · AARTIPHARM
27.8/100 · Adverse evidence · 90% evidence
Exact sum: 7.3 + 11.7 + 3.3 + 5.5 = 27.8
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7.3/35Growth & earnings
Revenue -14% · PAT -31.3% · OPM change -7 pp
88% evidence
11.7/25Capital efficiency
ROCE 10.7% · debt/equity 0.35×
100% evidence
3.3/20Valuation
P/E 34.6× · PEG 5.52
100% evidence
5.5/20Relative strength
RS sector -10.7% · RS bench -7% · 1Y -25.6%
70% evidence
14. Orchid Pharma Ltd · ORCHPHARMA
23.2/100 · Adverse evidence · 90% evidence
Exact sum: 6.1 + 6.4 + 2.7 + 8 = 23.2
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6.1/35Growth & earnings
Revenue -11.8% · PAT -79.8% · OPM change -1 pp
88% evidence
6.4/25Capital efficiency
ROCE 2.6% · debt/equity 0.28×
100% evidence
2.7/20Valuation
P/E 185× · PEG 4.09
100% evidence
8.0/20Relative strength
RS sector -19.8% · RS bench 39.4% · 1Y 42.2%
70% evidence
01 · compare level, then change
Revenue Scale & Growth Durability
Aarti Drugs Ltd has the highest Revenue among the 14 Pharma - API companies compared here, at ₹2,566 crore. Aarti Pharmalabs Ltd is next at ₹1,819 crore. Ind-Swift Laboratories Ltd has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Aarti Drugs Ltd is the scale leader at ₹2,566 crore, 41.1% ahead of Aarti Pharmalabs Ltd. Ind-Swift Laboratories Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 101% from a ₹627 crore base, with 14 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderAarti Drugs Ltd · ₹2,566 crore
Gap41.1% versus #2 · Aarti Pharmalabs Ltd
Persistence5/8 recent comparable periods
Coverage14/14 companies · 215 observations
Investor read: Aarti Drugs Ltd is the scale benchmark; Ind-Swift Laboratories Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Aarti Drugs Ltd's growth falls below Ind-Swift Laboratories Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Aarti Drugs Ltd AARTIDRUGS₹2.6K Cr
2Aarti Pharmalabs Ltd AARTIPHARM₹1.8K Cr
3Innova Captab Ltd INNOVACAP₹1.6K Cr
4Orchid Pharma Ltd ORCHPHARMA₹812 Cr
5Anuh Pharma Ltd ANUHPHR⚠ unverified₹771 Cr
Revenue growthfastest growers
1Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified100%
2Senores Pharmaceuticals Ltd SENORES62%
3Innova Captab Ltd INNOVACAP31%
4Anuh Pharma Ltd ANUHPHR⚠ unverified17%
5Wanbury Ltd WANBURY⚠ unverified17%
Revenue · company comparison
14/14 level · 14/14 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Aarti Drugs Ltd AARTIDRUGS | ₹720 Cr | 6.4% | Mar 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | ₹583 Cr | 3.4% | Mar 2026 |
| Innova Captab Ltd INNOVACAP | ₹448 Cr | 42% | Mar 2026 |
| Orchid Pharma Ltd ORCHPHARMA | ₹238 Cr | 0.4% | Mar 2026 |
| Kopran Ltd KOPRAN⚠ unverified | ₹234 Cr | 36% | Mar 2026 |
| Anuh Pharma Ltd ANUHPHR⚠ unverified | ₹202 Cr | 2.0% | Mar 2026 |
| Senores Pharmaceuticals Ltd SENORES | ₹175 Cr | 54% | Mar 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified | ₹170 Cr | 23% | Mar 2026 |
| Wanbury Ltd WANBURY⚠ unverified | ₹162 Cr | 22% | Mar 2026 |
| Beta Drugs Ltd BETA | ₹126 Cr | 26% | Jun 2026 |
| Fermenta Biotech Ltd FERMENTA⚠ unverified | ₹122 Cr | -13% | Mar 2026 |
| Themis Medicare Ltd THEMISMED⚠ unverified | ₹77 Cr | 6.7% | Mar 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified | ₹64 Cr | 9.6% | Mar 2026 |
| Gujarat Themis Biosyn Ltd GUJTHEM | ₹44 Cr | 16% | Mar 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
₹580 Cr
₹635 Cr
₹694 Cr
₹622 Cr
₹688 Cr
₹664 Cr
₹742 Cr
₹661 Cr
₹642 Cr
₹606 Cr
₹620 Cr
₹555 Cr
₹598 Cr
₹557 Cr
₹677 Cr
₹591 Cr
₹653 Cr
₹602 Cr
₹720 Cr
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
₹600 Cr
₹600 Cr
₹457 Cr
₹531 Cr
₹472 Cr
₹485 Cr
₹458 Cr
₹440 Cr
₹449 Cr
₹506 Cr
₹555 Cr
₹458 Cr
₹538 Cr
₹564 Cr
₹386 Cr
₹418 Cr
₹432 Cr
₹583 Cr
—
Beta Drugs Ltd · BETA
₹88 Cr
—
₹96 Cr
—
₹112 Cr
—
₹115 Cr
—
₹141 Cr
—
₹154 Cr
—
₹180 Cr
₹88 Cr
₹94 Cr
₹100 Cr
₹103 Cr
₹87 Cr
₹94 Cr
₹126 Cr
Fermenta Biotech Ltd · FERMENTA⚠ unverified
—
—
—
—
—
₹55 Cr
₹105 Cr
₹82 Cr
₹57 Cr
₹99 Cr
₹97 Cr
₹78 Cr
₹95 Cr
₹156 Cr
₹140 Cr
₹136 Cr
₹130 Cr
₹137 Cr
₹122 Cr
—
Gujarat Themis Biosyn Ltd · GUJTHEM
₹35 Cr
₹19 Cr
₹29 Cr
₹45 Cr
₹48 Cr
₹28 Cr
₹28 Cr
₹50 Cr
₹40 Cr
₹39 Cr
₹42 Cr
₹39 Cr
₹35 Cr
₹40 Cr
₹38 Cr
₹36 Cr
₹42 Cr
₹43 Cr
₹44 Cr
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
—
—
—
—
—
₹313 Cr
₹304 Cr
₹310 Cr
₹290 Cr
₹288 Cr
₹529 Cr
₹33 Cr
₹12 Cr
₹129 Cr
₹138 Cr
₹153 Cr
₹153 Cr
₹151 Cr
₹170 Cr
—
Innova Captab Ltd · INNOVACAP
—
—
₹216 Cr
₹222 Cr
₹242 Cr
₹242 Cr
₹241 Cr
₹233 Cr
₹283 Cr
₹302 Cr
₹263 Cr
₹294 Cr
₹318 Cr
₹316 Cr
₹315 Cr
₹352 Cr
₹380 Cr
₹450 Cr
₹448 Cr
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
—
—
—
—
—
₹60 Cr
₹55 Cr
₹60 Cr
₹58 Cr
₹47 Cr
₹43 Cr
₹61 Cr
₹75 Cr
₹74 Cr
₹59 Cr
₹76 Cr
₹74 Cr
₹73 Cr
₹64 Cr
—
Orchid Pharma Ltd · ORCHPHARMA
₹128 Cr
₹161 Cr
₹178 Cr
₹131 Cr
₹165 Cr
₹160 Cr
₹210 Cr
₹183 Cr
₹199 Cr
₹221 Cr
₹217 Cr
₹244 Cr
₹223 Cr
₹217 Cr
₹237 Cr
₹173 Cr
₹194 Cr
₹207 Cr
₹238 Cr
—
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
—
—
—
₹79 Cr
₹102 Cr
₹80 Cr
₹101 Cr
₹103 Cr
₹114 Cr
₹138 Cr
₹162 Cr
₹171 Cr
₹175 Cr
—
Themis Medicare Ltd · THEMISMED⚠ unverified
—
—
—
—
—
₹89 Cr
₹80 Cr
₹97 Cr
₹105 Cr
₹83 Cr
₹98 Cr
₹123 Cr
₹117 Cr
₹94 Cr
₹72 Cr
₹98 Cr
₹78 Cr
₹90 Cr
₹77 Cr
—
Wanbury Ltd · WANBURY⚠ unverified
—
—
—
₹117 Cr
₹124 Cr
₹126 Cr
₹133 Cr
₹146 Cr
₹144 Cr
₹146 Cr
₹139 Cr
₹131 Cr
₹161 Cr
₹133 Cr
₹172 Cr
₹163 Cr
₹160 Cr
₹162 Cr
—
—
Revenue growth · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
—
—
—
7.2%
19%
4.6%
6.9%
6.3%
-6.7%
-8.7%
-16%
-16%
-6.9%
-8.1%
9.2%
6.5%
9.2%
8.1%
6.4%
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
-21%
-19%
0.2%
-17%
-4.9%
4.3%
21%
4.1%
20%
11%
-30%
-8.7%
-20%
3.4%
—
Beta Drugs Ltd · BETA
73%
—
48%
—
27%
—
20%
—
26%
—
34%
—
28%
—
-39%
—
-43%
-1.1%
0.0%
26%
Fermenta Biotech Ltd · FERMENTA⚠ unverified
—
—
—
—
—
—
—
—
—
80%
-7.6%
-4.9%
67%
58%
44%
74%
37%
-12%
-13%
—
Gujarat Themis Biosyn Ltd · GUJTHEM
—
—
—
41%
37%
47%
-3.5%
11%
-17%
39%
50%
-22%
-13%
2.6%
-9.5%
-7.7%
20%
7.5%
16%
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
—
—
—
—
—
—
—
—
—
-7.9%
74%
-89%
-96%
-55%
-74%
364%
1,175%
17%
23%
—
Innova Captab Ltd · INNOVACAP
—
—
—
—
—
—
12%
5.0%
17%
25%
9.1%
26%
12%
4.6%
20%
20%
20%
42%
42%
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
—
—
—
—
—
—
—
—
—
-21%
-22%
2.1%
29%
57%
35%
23%
-0.3%
-1.5%
9.6%
—
Orchid Pharma Ltd · ORCHPHARMA
—
—
—
42%
29%
-0.6%
18%
40%
21%
38%
3.3%
33%
12%
-1.8%
9.2%
-29%
-13%
-4.6%
0.4%
—
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
—
—
—
—
—
—
—
30%
12%
73%
60%
66%
54%
—
Themis Medicare Ltd · THEMISMED⚠ unverified
—
—
—
—
—
—
—
—
—
-7.3%
22%
27%
12%
14%
-27%
-21%
-33%
-3.9%
6.7%
—
Wanbury Ltd · WANBURY⚠ unverified
—
—
—
—
—
—
—
25%
16%
16%
4.5%
-10%
12%
-8.9%
24%
24%
-0.6%
22%
—
—
02 · compare level, then change
Operating Economics & Margin Trend
Gujarat Themis Biosyn Ltd has the highest OPM among the 14 Pharma - API companies compared here, at 44%. Senores Pharmaceuticals Ltd is next at 27%. Ind-Swift Laboratories Ltd has the highest Margin change at +19 percentage points, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Gujarat Themis Biosyn Ltd leads opm at 44%; Ind-Swift Laboratories Ltd leads margin change at +19 percentage points.
LeaderGujarat Themis Biosyn Ltd · 44%
Gap63% versus #2 · Senores Pharmaceuticals Ltd
Persistence6/8 recent comparable periods
Coverage14/14 companies · 248 observations
Investor read: Gujarat Themis Biosyn Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Gujarat Themis Biosyn Ltd GUJTHEM44%
2Senores Pharmaceuticals Ltd SENORES27%
3Beta Drugs Ltd BETA22%
4Aarti Pharmalabs Ltd AARTIPHARM19%
5Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified17%
Margin changefastest expanders
1Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified+19.0 pp
2Themis Medicare Ltd THEMISMED⚠ unverified+15.7 pp
3Senores Pharmaceuticals Ltd SENORES+10.0 pp
4Wanbury Ltd WANBURY⚠ unverified+6.0 pp
5Kopran Ltd KOPRAN⚠ unverified+4.0 pp
Operating margin · company comparison
14/14 level · 14/14 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Gujarat Themis Biosyn Ltd GUJTHEM | 44% | +2.0 pp | Mar 2026 |
| Senores Pharmaceuticals Ltd SENORES | 27% | +10.0 pp | Mar 2026 |
| Beta Drugs Ltd BETA | 22% | +2.0 pp | Jun 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | 19% | −7.0 pp | Mar 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified | 17% | +2.5 pp | Mar 2026 |
| Fermenta Biotech Ltd FERMENTA⚠ unverified | 16% | −10.0 pp | Mar 2026 |
| Wanbury Ltd WANBURY⚠ unverified | 16% | +6.0 pp | Mar 2026 |
| Innova Captab Ltd INNOVACAP | 15% | 0.0 pp | Mar 2026 |
| Kopran Ltd KOPRAN⚠ unverified | 14% | +4.0 pp | Mar 2026 |
| Aarti Drugs Ltd AARTIDRUGS | 13% | −1.0 pp | Mar 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified | 12% | +19.0 pp | Mar 2026 |
| Orchid Pharma Ltd ORCHPHARMA | 11% | −1.0 pp | Mar 2026 |
| Anuh Pharma Ltd ANUHPHR⚠ unverified | 10% | +1.0 pp | Mar 2026 |
| Themis Medicare Ltd THEMISMED⚠ unverified | 4.9% | +15.7 pp | Mar 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
13%
14%
12%
11%
11%
11%
13%
13%
12%
12%
14%
12%
11%
11%
14%
13%
13%
9.0%
13%
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
14%
16%
19%
17%
18%
16%
19%
20%
21%
23%
17%
20%
24%
26%
24%
18%
24%
19%
—
Beta Drugs Ltd · BETA
23%
—
24%
—
24%
—
23%
—
23%
—
18%
—
22%
21%
18%
20%
21%
19%
19%
22%
Fermenta Biotech Ltd · FERMENTA⚠ unverified
16%
2.4%
18%
5.3%
3.4%
-18%
18%
13%
-24%
25%
6.0%
1.0%
20%
34%
26%
21%
20%
18%
16%
—
Gujarat Themis Biosyn Ltd · GUJTHEM
53%
53%
45%
51%
51%
43%
52%
47%
42%
46%
50%
48%
44%
48%
42%
39%
49%
49%
44%
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
24%
21%
12%
19%
19%
17%
21%
19%
23%
18%
17%
-29%
-99%
-5.0%
-7.0%
2.0%
1.0%
3.0%
12%
—
Innova Captab Ltd · INNOVACAP
—
—
7.9%
11%
13%
14%
11%
13%
14%
15%
14%
14%
16%
15%
15%
15%
14%
15%
15%
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
16%
10%
1.5%
12%
21%
14%
9.8%
14%
14%
7.2%
6.1%
17%
22%
21%
15%
19%
22%
22%
17%
—
Orchid Pharma Ltd · ORCHPHARMA
8.9%
8.7%
14%
9.5%
11%
9.0%
19%
12%
12%
16%
13%
13%
14%
12%
12%
8.0%
-1.0%
1.0%
11%
—
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
—
—
—
19%
22%
27%
23%
25%
17%
25%
31%
29%
27%
—
Themis Medicare Ltd · THEMISMED⚠ unverified
22%
18%
18%
22%
23%
17%
13%
22%
12%
9.8%
9.5%
24%
15%
6.4%
-11%
-10%
-4.0%
11%
4.9%
—
Wanbury Ltd · WANBURY⚠ unverified
5.7%
7.1%
9.5%
-3.0%
5.0%
5.0%
11%
9.0%
12%
15%
13%
8.0%
12%
10%
17%
15%
16%
16%
—
—
Margin change · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
−7.4 pp
−5.8 pp
−3.7 pp
−3.0 pp
−1.9 pp
−3.2 pp
+0.6 pp
+2.2 pp
+1.2 pp
+1.0 pp
+1.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
0.0 pp
+1.0 pp
+2.0 pp
−2.0 pp
−1.0 pp
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
+4.3 pp
−0.4 pp
+0.2 pp
+3.1 pp
+3.0 pp
+7.0 pp
−2.0 pp
0.0 pp
+3.0 pp
+3.0 pp
+7.0 pp
−2.0 pp
0.0 pp
−7.0 pp
—
Beta Drugs Ltd · BETA
+2.0 pp
—
+2.0 pp
—
+1.0 pp
—
−1.0 pp
—
−1.0 pp
—
−5.0 pp
—
−1.0 pp
—
0.0 pp
—
−1.0 pp
−2.0 pp
+1.0 pp
+2.0 pp
Fermenta Biotech Ltd · FERMENTA⚠ unverified
−13.1 pp
−22.3 pp
+8.2 pp
−18.2 pp
−12.4 pp
−20.4 pp
−0.5 pp
+7.7 pp
−27.4 pp
+43.0 pp
−12.0 pp
−12.0 pp
+44.0 pp
+9.0 pp
+20.0 pp
+20.0 pp
0.0 pp
−16.0 pp
−10.0 pp
—
Gujarat Themis Biosyn Ltd · GUJTHEM
−1.6 pp
+8.9 pp
+9.9 pp
−0.9 pp
−1.5 pp
−9.7 pp
+6.5 pp
−3.7 pp
−9.2 pp
+3.0 pp
−2.0 pp
+1.0 pp
+2.0 pp
+2.0 pp
−8.0 pp
−9.0 pp
+5.0 pp
+1.0 pp
+2.0 pp
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
+2.2 pp
−0.2 pp
−6.4 pp
−1.6 pp
−4.9 pp
−4.1 pp
+9.0 pp
+0.1 pp
+4.1 pp
+0.8 pp
−4.0 pp
−48.0 pp
−122.0 pp
−23.0 pp
−24.0 pp
+31.0 pp
+100.0 pp
+8.0 pp
+19.0 pp
—
Innova Captab Ltd · INNOVACAP
—
—
—
—
—
—
+3.1 pp
+2.3 pp
+1.2 pp
+1.0 pp
+3.0 pp
+1.0 pp
+2.0 pp
0.0 pp
+1.0 pp
+1.0 pp
−2.0 pp
0.0 pp
0.0 pp
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
+7.2 pp
−1.1 pp
−10.4 pp
−5.3 pp
+5.5 pp
+3.7 pp
+8.3 pp
+2.5 pp
−6.9 pp
−6.8 pp
−3.7 pp
+2.3 pp
+7.3 pp
+14.2 pp
+8.7 pp
+2.1 pp
+0.3 pp
+0.9 pp
+2.5 pp
—
Orchid Pharma Ltd · ORCHPHARMA
−7.7 pp
+13.5 pp
+17.6 pp
+12.8 pp
+1.9 pp
+0.3 pp
+4.5 pp
+2.5 pp
+1.2 pp
+7.0 pp
−6.0 pp
+1.0 pp
+2.0 pp
−4.0 pp
−1.0 pp
−5.0 pp
−15.0 pp
−11.0 pp
−1.0 pp
—
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
—
—
—
—
—
—
—
+6.0 pp
−5.0 pp
−2.0 pp
+8.0 pp
+4.0 pp
+10.0 pp
—
Themis Medicare Ltd · THEMISMED⚠ unverified
+4.2 pp
−5.0 pp
−1.8 pp
−14.4 pp
+1.6 pp
−1.2 pp
−5.0 pp
+0.9 pp
−11.6 pp
−7.2 pp
−3.6 pp
+1.2 pp
+2.8 pp
−3.4 pp
−20.2 pp
−34.2 pp
−18.6 pp
+4.5 pp
+15.7 pp
—
Wanbury Ltd · WANBURY⚠ unverified
−3.7 pp
−5.5 pp
+11.0 pp
−8.1 pp
−0.7 pp
−2.1 pp
+1.5 pp
+12.0 pp
+7.0 pp
+10.0 pp
+2.0 pp
−1.0 pp
0.0 pp
−5.0 pp
+4.0 pp
+7.0 pp
+4.0 pp
+6.0 pp
—
—
03 · compare level, then change
Profit Scale & Acceleration
Aarti Drugs Ltd has the highest Net profit among the 14 Pharma - API companies compared here, at ₹195 crore. Aarti Pharmalabs Ltd is next at ₹187 crore. Senores Pharmaceuticals Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Aarti Drugs Ltd leads with ₹195 crore of TTM profit, 4.3% above Aarti Pharmalabs Ltd. Senores Pharmaceuticals Ltd shows ≥100% on the scoring scale (110.3% uncapped) growth from a ₹122 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderAarti Drugs Ltd · ₹195 crore
Gap4.3% versus #2 · Aarti Pharmalabs Ltd
Persistence4/8 recent comparable periods
Coverage14/14 companies · 216 observations
Investor read: Aarti Drugs Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Aarti Drugs Ltd AARTIDRUGS₹195 Cr
2Aarti Pharmalabs Ltd AARTIPHARM₹187 Cr
3Innova Captab Ltd INNOVACAP₹141 Cr
4Senores Pharmaceuticals Ltd SENORES₹122 Cr
5Fermenta Biotech Ltd FERMENTA⚠ unverified₹71 Cr
Profit growthfastest growers
1Senores Pharmaceuticals Ltd SENORES100%
2Wanbury Ltd WANBURY⚠ unverified46%
3Aarti Drugs Ltd AARTIDRUGS16%
4Innova Captab Ltd INNOVACAP10%
5Gujarat Themis Biosyn Ltd GUJTHEM-6.1%
Net profit · company comparison
14/14 level · 13/14 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Aarti Pharmalabs Ltd AARTIPHARM | ₹61 Cr | -31% | Mar 2026 |
| Aarti Drugs Ltd AARTIDRUGS | ₹55 Cr | -13% | Mar 2026 |
| Innova Captab Ltd INNOVACAP | ₹38 Cr | 27% | Mar 2026 |
| Senores Pharmaceuticals Ltd SENORES | ₹37 Cr | 106% | Mar 2026 |
| Orchid Pharma Ltd ORCHPHARMA | ₹24 Cr | 9.1% | Mar 2026 |
| Fermenta Biotech Ltd FERMENTA⚠ unverified | ₹19 Cr | -42% | Mar 2026 |
| Kopran Ltd KOPRAN⚠ unverified | ₹19 Cr | 90% | Mar 2026 |
| Beta Drugs Ltd BETA | ₹16 Cr | 33% | Jun 2026 |
| Wanbury Ltd WANBURY⚠ unverified | ₹16 Cr | 1,500% | Mar 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified | ₹15 Cr | -93% | Mar 2026 |
| Anuh Pharma Ltd ANUHPHR⚠ unverified | ₹12 Cr | 0.0% | Mar 2026 |
| Gujarat Themis Biosyn Ltd GUJTHEM | ₹11 Cr | -8.3% | Mar 2026 |
| Themis Medicare Ltd THEMISMED⚠ unverified | ₹9 Cr | 1,840% | Mar 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified | ₹9 Cr | 33% | Mar 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
₹43 Cr
₹58 Cr
₹55 Cr
₹35 Cr
₹39 Cr
₹37 Cr
₹56 Cr
₹48 Cr
₹40 Cr
₹37 Cr
₹47 Cr
₹33 Cr
₹35 Cr
₹37 Cr
₹63 Cr
₹54 Cr
₹45 Cr
₹41 Cr
₹55 Cr
—
Aarti Pharmalabs Ltd · AARTIPHARM
₹0 Cr
₹61 Cr
₹61 Cr
₹52 Cr
₹51 Cr
₹48 Cr
₹43 Cr
₹47 Cr
₹52 Cr
₹53 Cr
₹65 Cr
₹55 Cr
₹55 Cr
₹74 Cr
₹88 Cr
₹50 Cr
₹28 Cr
₹48 Cr
₹61 Cr
—
Beta Drugs Ltd · BETA
₹12 Cr
—
₹13 Cr
—
₹16 Cr
—
₹15 Cr
—
₹20 Cr
—
₹17 Cr
—
₹24 Cr
₹9 Cr
₹9 Cr
₹12 Cr
₹12 Cr
₹9 Cr
₹9 Cr
₹16 Cr
Fermenta Biotech Ltd · FERMENTA⚠ unverified
—
—
—
—
—
₹-38 Cr
₹-5 Cr
₹2 Cr
₹-29 Cr
₹10 Cr
₹-7 Cr
₹-6 Cr
₹11 Cr
₹38 Cr
₹33 Cr
₹22 Cr
₹18 Cr
₹12 Cr
₹19 Cr
—
Gujarat Themis Biosyn Ltd · GUJTHEM
₹14 Cr
₹7 Cr
₹10 Cr
₹18 Cr
₹19 Cr
₹10 Cr
₹12 Cr
₹18 Cr
₹13 Cr
₹13 Cr
₹16 Cr
₹13 Cr
₹11 Cr
₹13 Cr
₹12 Cr
₹9 Cr
₹14 Cr
₹12 Cr
₹11 Cr
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
—
—
—
—
—
₹28 Cr
₹-25 Cr
₹17 Cr
₹32 Cr
₹19 Cr
₹494 Cr
₹1 Cr
₹0 Cr
₹-5 Cr
₹222 Cr
₹9 Cr
₹8 Cr
₹10 Cr
₹15 Cr
—
Innova Captab Ltd · INNOVACAP
—
—
₹13 Cr
₹16 Cr
₹19 Cr
₹20 Cr
₹17 Cr
₹18 Cr
₹23 Cr
₹25 Cr
₹29 Cr
₹29 Cr
₹35 Cr
₹34 Cr
₹30 Cr
₹31 Cr
₹30 Cr
₹42 Cr
₹38 Cr
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
—
—
—
—
—
₹8 Cr
₹6 Cr
₹7 Cr
₹7 Cr
₹4 Cr
₹4 Cr
₹5 Cr
₹11 Cr
₹32 Cr
₹7 Cr
₹11 Cr
₹13 Cr
₹11 Cr
₹9 Cr
—
Orchid Pharma Ltd · ORCHPHARMA
₹49 Cr
₹-14 Cr
₹-7 Cr
₹-15 Cr
₹-5 Cr
₹8 Cr
₹59 Cr
₹9 Cr
₹20 Cr
₹29 Cr
₹33 Cr
₹29 Cr
₹27 Cr
₹21 Cr
₹22 Cr
₹15 Cr
₹-6 Cr
₹-13 Cr
₹24 Cr
—
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
—
—
—
₹7 Cr
₹14 Cr
₹11 Cr
₹13 Cr
₹16 Cr
₹18 Cr
₹21 Cr
₹30 Cr
₹34 Cr
₹37 Cr
—
Themis Medicare Ltd · THEMISMED⚠ unverified
—
—
—
—
—
₹13 Cr
₹8 Cr
₹18 Cr
₹11 Cr
₹7 Cr
₹7 Cr
₹25 Cr
₹14 Cr
₹1 Cr
₹-10 Cr
₹-14 Cr
₹-4 Cr
₹10 Cr
₹9 Cr
—
Wanbury Ltd · WANBURY⚠ unverified
—
—
—
₹-7 Cr
₹-1 Cr
₹-3 Cr
₹1 Cr
₹5 Cr
₹7 Cr
₹10 Cr
₹34 Cr
₹1 Cr
₹8 Cr
₹1 Cr
₹20 Cr
₹13 Cr
₹15 Cr
₹16 Cr
—
—
Profit growth · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
—
—
—
-29%
-9.3%
-36%
1.8%
37%
2.6%
0.0%
-16%
-31%
-13%
0.0%
34%
64%
29%
11%
-13%
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
-21%
-30%
-9.6%
2.0%
10%
51%
17%
5.8%
40%
35%
-9.1%
-49%
-35%
-31%
—
Beta Drugs Ltd · BETA
140%
—
86%
—
33%
—
15%
—
25%
—
13%
—
20%
—
-47%
—
-50%
0.0%
0.0%
33%
Fermenta Biotech Ltd · FERMENTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
-400%
—
280%
—
—
64%
-68%
-42%
—
Gujarat Themis Biosyn Ltd · GUJTHEM
—
—
—
38%
36%
43%
20%
0.0%
-32%
30%
33%
-28%
-15%
0.0%
-25%
-31%
27%
-7.7%
-8.3%
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
—
—
—
—
—
—
—
—
—
-31%
—
-94%
-100%
-126%
-55%
800%
—
—
-93%
—
Innova Captab Ltd · INNOVACAP
—
—
—
—
—
—
31%
13%
21%
25%
71%
61%
52%
36%
3.5%
6.9%
-14%
24%
27%
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
—
—
—
—
—
—
—
—
—
-51%
-37%
-29%
53%
708%
85%
103%
9.7%
-66%
33%
—
Orchid Pharma Ltd · ORCHPHARMA
—
—
—
—
-110%
—
—
—
—
263%
-44%
222%
35%
-28%
-33%
-48%
-122%
-162%
9.1%
—
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
—
—
—
—
—
—
—
129%
29%
91%
131%
113%
106%
—
Themis Medicare Ltd · THEMISMED⚠ unverified
—
—
—
—
—
—
—
—
—
-43%
-21%
36%
26%
-93%
-245%
-158%
-125%
1,840%
—
—
Wanbury Ltd · WANBURY⚠ unverified
—
—
—
—
—
—
—
—
—
—
3,300%
-80%
14%
-90%
-41%
1,200%
88%
1,500%
—
—
04 · compare level, then change
Capacity Spending & Returns On It
Innova Captab Ltd has the highest CAPEX among the 14 Pharma - API companies compared here, at ₹121 crore. Aarti Pharmalabs Ltd is next at ₹16 crore. The same company also holds the highest CAPEX intensity, at 42.8%. 2 of 14 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Innova Captab Ltd reports ₹121 crore of CAPEX; Innova Captab Ltd has the highest covered intensity at 42.8%. Coverage is only 2 of 14 companies and 9 reported observations, so this is partial evidence—not a complete sector rank.
LeaderInnova Captab Ltd · ₹121 crore
Gap656.3% versus #2 · Aarti Pharmalabs Ltd
Persistence5/5 recent comparable periods
Coverage2/14 companies · 9 observations
Investor read: Use the CAPEX rank as a diligence queue. Verify commissioning, utilization, cash conversion and post-investment ROCE before treating spend as value creation.
This conclusion weakens if: CAPEX rises without higher utilization, operating cash flow or incremental returns.
CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.
CAPEXlargest spenders
1Innova Captab Ltd INNOVACAP₹121 Cr
2Aarti Pharmalabs Ltd AARTIPHARM₹16 Cr
CAPEX intensityhighest reinvestment intensity
1Innova Captab Ltd INNOVACAP43%
2Aarti Pharmalabs Ltd AARTIPHARM3.3%
Capital expenditure · company comparison
2/14 level · 2/14 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
Withheld from this chart: Senores Pharmaceuticals Ltd (SENORES) — its two data sources disagree by up to 13% on reported income across 10 comparable periods, so its derived ratios are withheld; Beta Drugs Ltd (BETA) — its two data sources disagree by up to 50% on reported income across 11 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | CAPEX | CAPEX intensity | Reported |
|---|---|---|---|
| Innova Captab Ltd INNOVACAP | ₹121 Cr | 43% | Mar 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | ₹16 Cr | 3.3% | Mar 2026 |
Full 20-quarter history · every available company
CAPEX · reported quarter history
Aarti Pharmalabs Ltd · AARTIPHARM
—
₹71 Cr
₹71 Cr
—
—
₹26 Cr
₹16 Cr
—
—
—
—
—
—
—
—
—
—
—
—
—
Innova Captab Ltd · INNOVACAP
—
—
₹11 Cr
₹18 Cr
₹18 Cr
—
—
₹30 Cr
₹121 Cr
—
—
—
—
—
—
—
—
—
—
—
CAPEX intensity · reported quarter history
Aarti Pharmalabs Ltd · AARTIPHARM
—
12%
12%
—
—
5.5%
3.3%
—
—
—
—
—
—
—
—
—
—
—
—
—
Innova Captab Ltd · INNOVACAP
—
—
5.1%
8.1%
7.4%
—
—
13%
43%
—
—
—
—
—
—
—
—
—
—
—
Annual capital allocation · 10-year view
14/14 capacity base · 14/14 OCF · 14/14 CAPEX · 14/14 FCF
Capacity base is net fixed assets plus capital work in progress, straight off the reported balance sheet. It is not cash spent, so it answers a narrower question than CAPEX — but it is reported for companies whose cash-flow CAPEX is not published, which is why it leads here. Missing years remain blank; annual values are never relabelled as quarters.
Full annual capacity base, operating cash flow, CAPEX and free cash flow history
Capacity base · net fixed assets + CWIP · fiscal-year history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
₹595 Cr
₹630 Cr
₹658 Cr
₹656 Cr
₹684 Cr
₹767 Cr
₹886 Cr
₹1.1K Cr
₹1.2K Cr
₹1.3K Cr
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
₹0 Cr
₹969 Cr
₹1.0K Cr
₹1.2K Cr
₹1.5K Cr
₹1.8K Cr
Beta Drugs Ltd · BETA
₹8 Cr
₹14 Cr
₹33 Cr
₹44 Cr
₹43 Cr
₹55 Cr
₹63 Cr
₹65 Cr
₹89 Cr
₹125 Cr
Fermenta Biotech Ltd · FERMENTA⚠ unverified
₹177 Cr
₹181 Cr
₹200 Cr
₹271 Cr
₹320 Cr
₹334 Cr
₹312 Cr
₹271 Cr
₹243 Cr
₹233 Cr
Gujarat Themis Biosyn Ltd · GUJTHEM
₹11 Cr
₹11 Cr
₹16 Cr
₹17 Cr
₹21 Cr
₹32 Cr
₹54 Cr
₹129 Cr
₹225 Cr
₹410 Cr
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
₹1.1K Cr
₹1.0K Cr
₹934 Cr
₹854 Cr
₹772 Cr
₹640 Cr
₹595 Cr
₹8 Cr
₹273 Cr
₹316 Cr
Innova Captab Ltd · INNOVACAP
—
—
₹78 Cr
₹73 Cr
₹86 Cr
₹183 Cr
₹205 Cr
₹699 Cr
₹853 Cr
₹858 Cr
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
₹22 Cr
₹24 Cr
₹26 Cr
₹26 Cr
₹26 Cr
₹23 Cr
₹24 Cr
₹9 Cr
₹94 Cr
₹85 Cr
Orchid Pharma Ltd · ORCHPHARMA
₹1.8K Cr
₹1.7K Cr
₹1.5K Cr
₹884 Cr
₹677 Cr
₹594 Cr
₹619 Cr
₹651 Cr
₹714 Cr
₹1.0K Cr
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
₹15 Cr
₹61 Cr
₹332 Cr
₹473 Cr
₹772 Cr
Themis Medicare Ltd · THEMISMED⚠ unverified
₹133 Cr
₹128 Cr
₹125 Cr
₹124 Cr
₹135 Cr
₹147 Cr
₹165 Cr
₹171 Cr
₹175 Cr
₹169 Cr
Wanbury Ltd · WANBURY⚠ unverified
₹196 Cr
₹188 Cr
₹181 Cr
₹178 Cr
₹178 Cr
₹169 Cr
₹169 Cr
₹170 Cr
₹206 Cr
—
Operating cash flow · fiscal-year history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
₹175 Cr
₹70 Cr
₹143 Cr
₹251 Cr
₹155 Cr
₹70 Cr
₹133 Cr
₹359 Cr
₹245 Cr
₹254 Cr
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
₹0 Cr
₹-44 Cr
₹250 Cr
₹216 Cr
₹332 Cr
₹262 Cr
Beta Drugs Ltd · BETA
₹5 Cr
₹17 Cr
₹0 Cr
₹8 Cr
₹19 Cr
₹30 Cr
₹23 Cr
₹31 Cr
₹36 Cr
₹37 Cr
Fermenta Biotech Ltd · FERMENTA⚠ unverified
₹2 Cr
₹59 Cr
₹90 Cr
₹34 Cr
₹63 Cr
₹43 Cr
₹116 Cr
₹105 Cr
₹41 Cr
₹93 Cr
Gujarat Themis Biosyn Ltd · GUJTHEM
₹3 Cr
₹6 Cr
₹1 Cr
₹1 Cr
₹11 Cr
₹40 Cr
₹39 Cr
₹64 Cr
₹91 Cr
₹49 Cr
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
₹96 Cr
₹73 Cr
₹-64 Cr
₹125 Cr
₹135 Cr
₹150 Cr
₹195 Cr
₹-163 Cr
₹-25 Cr
₹-70 Cr
Innova Captab Ltd · INNOVACAP
—
—
₹19 Cr
₹31 Cr
₹42 Cr
₹59 Cr
₹67 Cr
₹146 Cr
₹64 Cr
₹117 Cr
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
₹-3 Cr
₹-2 Cr
₹31 Cr
₹11 Cr
₹28 Cr
₹7 Cr
₹47 Cr
₹35 Cr
₹55 Cr
₹47 Cr
Orchid Pharma Ltd · ORCHPHARMA
₹401 Cr
₹9 Cr
₹12 Cr
₹81 Cr
₹24 Cr
₹92 Cr
₹18 Cr
₹126 Cr
₹19 Cr
₹101 Cr
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
₹-10 Cr
₹-1 Cr
₹-26 Cr
₹-46 Cr
₹62 Cr
Themis Medicare Ltd · THEMISMED⚠ unverified
₹-2 Cr
₹8 Cr
₹11 Cr
₹0 Cr
₹57 Cr
₹34 Cr
₹16 Cr
₹22 Cr
₹35 Cr
₹-3 Cr
Wanbury Ltd · WANBURY⚠ unverified
₹43 Cr
₹32 Cr
₹30 Cr
₹44 Cr
₹17 Cr
₹41 Cr
₹20 Cr
₹4 Cr
₹26 Cr
₹32 Cr
CAPEX · reported cash flow · fiscal-year history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
₹106 Cr
₹75 Cr
₹71 Cr
₹47 Cr
₹78 Cr
₹133 Cr
₹169 Cr
₹237 Cr
₹180 Cr
₹171 Cr
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
₹1.0K Cr
₹122 Cr
₹215 Cr
₹428 Cr
₹423 Cr
Beta Drugs Ltd · BETA
₹2 Cr
₹8 Cr
₹22 Cr
₹15 Cr
₹6 Cr
₹19 Cr
₹18 Cr
₹12 Cr
₹37 Cr
₹53 Cr
Fermenta Biotech Ltd · FERMENTA⚠ unverified
₹13 Cr
₹16 Cr
₹31 Cr
₹86 Cr
₹69 Cr
₹40 Cr
₹6 Cr
₹-16 Cr
₹-4 Cr
₹12 Cr
Gujarat Themis Biosyn Ltd · GUJTHEM
₹3 Cr
₹1 Cr
₹6 Cr
₹2 Cr
₹6 Cr
₹13 Cr
₹25 Cr
₹79 Cr
₹101 Cr
₹198 Cr
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
₹23 Cr
₹-22 Cr
₹35 Cr
₹10 Cr
₹5 Cr
₹-1 Cr
₹12 Cr
₹-534 Cr
₹289 Cr
₹74 Cr
Innova Captab Ltd · INNOVACAP
—
—
—
₹5 Cr
₹19 Cr
₹105 Cr
₹33 Cr
₹510 Cr
₹179 Cr
₹50 Cr
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
₹-28 Cr
₹2 Cr
₹3 Cr
₹1 Cr
₹1 Cr
₹-1 Cr
₹2 Cr
₹-13 Cr
₹93 Cr
₹0 Cr
Orchid Pharma Ltd · ORCHPHARMA
₹9 Cr
₹6 Cr
₹6 Cr
₹-532 Cr
₹-98 Cr
₹4 Cr
₹80 Cr
₹65 Cr
₹98 Cr
₹354 Cr
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
₹48 Cr
₹281 Cr
₹158 Cr
₹330 Cr
Themis Medicare Ltd · THEMISMED⚠ unverified
₹17 Cr
₹2 Cr
₹5 Cr
₹7 Cr
₹20 Cr
₹21 Cr
₹28 Cr
₹18 Cr
₹14 Cr
₹4 Cr
Wanbury Ltd · WANBURY⚠ unverified
₹12 Cr
₹2 Cr
₹3 Cr
₹7 Cr
₹10 Cr
₹2 Cr
₹12 Cr
₹14 Cr
₹49 Cr
—
Free cash flow · fiscal-year history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
₹69 Cr
₹-5 Cr
₹72 Cr
₹204 Cr
₹77 Cr
₹-63 Cr
₹-36 Cr
₹122 Cr
₹65 Cr
₹83 Cr
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
₹-1.1K Cr
₹128 Cr
₹1 Cr
₹-96 Cr
₹-161 Cr
Beta Drugs Ltd · BETA
₹3 Cr
₹9 Cr
₹-22 Cr
₹-7 Cr
₹13 Cr
₹11 Cr
₹5 Cr
₹19 Cr
₹-1 Cr
₹-16 Cr
Fermenta Biotech Ltd · FERMENTA⚠ unverified
₹-11 Cr
₹43 Cr
₹59 Cr
₹-52 Cr
₹-6 Cr
₹3 Cr
₹110 Cr
₹121 Cr
₹45 Cr
₹81 Cr
Gujarat Themis Biosyn Ltd · GUJTHEM
₹0 Cr
₹5 Cr
₹-5 Cr
₹-1 Cr
₹5 Cr
₹27 Cr
₹14 Cr
₹-15 Cr
₹-10 Cr
₹-149 Cr
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
₹73 Cr
₹95 Cr
₹-99 Cr
₹115 Cr
₹130 Cr
₹151 Cr
₹183 Cr
₹371 Cr
₹-314 Cr
₹-144 Cr
Innova Captab Ltd · INNOVACAP
—
—
—
₹26 Cr
₹23 Cr
₹-46 Cr
₹34 Cr
₹-364 Cr
₹-115 Cr
₹67 Cr
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
₹25 Cr
₹-4 Cr
₹28 Cr
₹10 Cr
₹27 Cr
₹8 Cr
₹45 Cr
₹48 Cr
₹-38 Cr
₹47 Cr
Orchid Pharma Ltd · ORCHPHARMA
₹392 Cr
₹3 Cr
₹6 Cr
₹613 Cr
₹122 Cr
₹88 Cr
₹-62 Cr
₹61 Cr
₹-79 Cr
₹-253 Cr
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
₹-49 Cr
₹-307 Cr
₹-204 Cr
₹-268 Cr
Themis Medicare Ltd · THEMISMED⚠ unverified
₹-19 Cr
₹6 Cr
₹6 Cr
₹-7 Cr
₹37 Cr
₹13 Cr
₹-12 Cr
₹4 Cr
₹21 Cr
₹-7 Cr
Wanbury Ltd · WANBURY⚠ unverified
₹31 Cr
₹30 Cr
₹27 Cr
₹37 Cr
₹7 Cr
₹39 Cr
₹8 Cr
₹-10 Cr
₹-23 Cr
—
05 · compare level, then change
Debt Load & Balance-Sheet Headroom
Anuh Pharma Ltd has the lowest Gross debt among the 14 Pharma - API companies compared here, at ₹0 crore. Jagsonpal Pharmaceuticals Ltd is next at ₹8 crore. Ind-Swift Laboratories Ltd has the lowest Net debt at ₹421 crore net cash, so level and change sit with different companies.
What the numbers say: Ind-Swift Laboratories Ltd has the clearest covered balance-sheet capacity with ₹421 crore net cash and gross debt of ₹18 crore. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.
LeaderAnuh Pharma Ltd · ₹0 crore
Gap100% versus #2 · Jagsonpal Pharmaceuticals Ltd
Persistence8/8 recent comparable periods
Coverage14/14 companies · 229 observations
Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.
This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.
Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.
Gross debtlowest gross debt
1Anuh Pharma Ltd ANUHPHR⚠ unverified₹0 Cr
2Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified₹8 Cr
3Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified₹18 Cr
4Themis Medicare Ltd THEMISMED⚠ unverified₹100 Cr
5Fermenta Biotech Ltd FERMENTA⚠ unverified₹113 Cr
Net debtlowest net debt
1Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified₹-421 Cr
2Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified₹-98 Cr
3Anuh Pharma Ltd ANUHPHR⚠ unverified₹-53 Cr
4Fermenta Biotech Ltd FERMENTA⚠ unverified₹80 Cr
5Themis Medicare Ltd THEMISMED⚠ unverified₹91 Cr
Debt and balance-sheet capacity · company comparison
14/14 level · 12/14 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Gross debt | Net debt | Reported |
|---|---|---|---|
| Aarti Pharmalabs Ltd AARTIPHARM | ₹754 Cr | ₹784 Cr | Mar 2026 |
| Aarti Drugs Ltd AARTIDRUGS | ₹577 Cr | ₹553 Cr | Mar 2026 |
| Orchid Pharma Ltd ORCHPHARMA | ₹363 Cr | ₹280 Cr | Mar 2026 |
| Innova Captab Ltd INNOVACAP | ₹344 Cr | ₹276 Cr | Mar 2026 |
| Senores Pharmaceuticals Ltd SENORES | ₹342 Cr | — | Mar 2026 |
| Wanbury Ltd WANBURY⚠ unverified | ₹224 Cr | ₹216 Cr | Mar 2026 |
| Gujarat Themis Biosyn Ltd GUJTHEM | ₹162 Cr | ₹156 Cr | Mar 2026 |
| Kopran Ltd KOPRAN⚠ unverified | ₹153 Cr | ₹146 Cr | Mar 2026 |
| Beta Drugs Ltd BETA | ₹148 Cr | — | Jun 2026 |
| Fermenta Biotech Ltd FERMENTA⚠ unverified | ₹113 Cr | ₹80 Cr | Mar 2026 |
| Themis Medicare Ltd THEMISMED⚠ unverified | ₹100 Cr | ₹91 Cr | Mar 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified | ₹18 Cr | ₹-421 Cr | Mar 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified | ₹8 Cr | ₹-98 Cr | Mar 2026 |
| Anuh Pharma Ltd ANUHPHR⚠ unverified | ₹0 Cr | ₹-53 Cr | Mar 2026 |
Full 20-quarter history · every available company
Gross debt · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
₹470 Cr
₹470 Cr
₹543 Cr
₹543 Cr
₹586 Cr
₹586 Cr
₹609 Cr
₹609 Cr
₹589 Cr
₹589 Cr
₹564 Cr
₹564 Cr
₹590 Cr
₹590 Cr
₹615 Cr
₹615 Cr
₹573 Cr
₹573 Cr
₹577 Cr
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
₹341 Cr
₹338 Cr
—
—
₹300 Cr
₹215 Cr
₹231 Cr
₹217 Cr
₹217 Cr
₹285 Cr
₹285 Cr
₹386 Cr
₹386 Cr
₹413 Cr
₹413 Cr
₹659 Cr
₹675 Cr
₹754 Cr
—
Beta Drugs Ltd · BETA
—
—
₹21 Cr
—
—
—
₹20 Cr
—
—
—
₹15 Cr
—
—
—
₹138 Cr
—
₹146 Cr
—
₹148 Cr
—
Fermenta Biotech Ltd · FERMENTA⚠ unverified
₹224 Cr
₹224 Cr
₹239 Cr
—
—
—
₹220 Cr
₹220 Cr
₹172 Cr
₹172 Cr
₹139 Cr
₹139 Cr
₹125 Cr
₹125 Cr
₹115 Cr
₹115 Cr
₹112 Cr
₹112 Cr
₹113 Cr
—
Gujarat Themis Biosyn Ltd · GUJTHEM
₹2 Cr
₹2 Cr
₹1 Cr
₹1 Cr
₹1 Cr
₹1 Cr
₹0 Cr
₹0 Cr
₹2 Cr
₹2 Cr
₹3 Cr
₹3 Cr
₹3 Cr
₹3 Cr
₹30 Cr
₹30 Cr
₹71 Cr
₹71 Cr
₹162 Cr
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
₹973 Cr
₹973 Cr
₹953 Cr
₹953 Cr
₹916 Cr
₹916 Cr
₹862 Cr
₹862 Cr
₹802 Cr
₹802 Cr
₹17 Cr
₹17 Cr
₹16 Cr
₹16 Cr
₹41 Cr
₹41 Cr
₹22 Cr
₹22 Cr
₹18 Cr
—
Innova Captab Ltd · INNOVACAP
—
—
₹199 Cr
₹199 Cr
—
—
₹237 Cr
₹444 Cr
₹520 Cr
₹520 Cr
₹245 Cr
₹245 Cr
₹261 Cr
₹261 Cr
₹338 Cr
₹338 Cr
₹336 Cr
₹336 Cr
₹344 Cr
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
₹7 Cr
₹7 Cr
₹0 Cr
—
₹6 Cr
₹6 Cr
₹6 Cr
₹6 Cr
₹9 Cr
₹9 Cr
₹9 Cr
₹9 Cr
₹10 Cr
₹10 Cr
₹9 Cr
₹9 Cr
₹9 Cr
₹9 Cr
₹8 Cr
—
Orchid Pharma Ltd · ORCHPHARMA
₹301 Cr
₹301 Cr
₹268 Cr
₹268 Cr
₹339 Cr
₹339 Cr
₹331 Cr
₹331 Cr
₹147 Cr
₹147 Cr
₹135 Cr
₹135 Cr
₹165 Cr
₹165 Cr
₹175 Cr
₹175 Cr
₹282 Cr
₹282 Cr
₹363 Cr
—
Senores Pharmaceuticals Ltd · SENORES
—
—
₹15 Cr
—
—
—
₹63 Cr
—
—
—
₹258 Cr
—
—
—
₹315 Cr
—
₹241 Cr
—
₹342 Cr
—
Themis Medicare Ltd · THEMISMED⚠ unverified
₹67 Cr
₹67 Cr
₹80 Cr
₹80 Cr
₹76 Cr
₹76 Cr
₹92 Cr
₹92 Cr
₹95 Cr
₹95 Cr
₹96 Cr
₹96 Cr
₹81 Cr
₹81 Cr
₹83 Cr
₹83 Cr
₹96 Cr
₹96 Cr
₹100 Cr
—
Wanbury Ltd · WANBURY⚠ unverified
₹164 Cr
₹164 Cr
₹100 Cr
₹74 Cr
₹66 Cr
₹66 Cr
₹95 Cr
₹68 Cr
₹113 Cr
₹113 Cr
₹116 Cr
₹116 Cr
₹181 Cr
₹181 Cr
₹179 Cr
₹177 Cr
₹196 Cr
₹196 Cr
₹224 Cr
—
Net debt · reported quarter history
Aarti Drugs Ltd · AARTIDRUGS
₹450 Cr
₹450 Cr
₹509 Cr
₹509 Cr
₹559 Cr
₹559 Cr
₹589 Cr
₹588 Cr
₹564 Cr
₹564 Cr
₹544 Cr
₹543 Cr
₹560 Cr
₹560 Cr
₹593 Cr
₹592 Cr
₹548 Cr
₹548 Cr
₹553 Cr
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
₹258 Cr
₹258 Cr
—
—
₹195 Cr
₹152 Cr
₹168 Cr
₹147 Cr
₹147 Cr
₹191 Cr
₹191 Cr
₹286 Cr
₹286 Cr
₹365 Cr
₹357 Cr
₹619 Cr
₹619 Cr
₹784 Cr
—
Anuh Pharma Ltd · ANUHPHR⚠ unverified
₹-10 Cr
₹-10 Cr
₹-21 Cr
₹-21 Cr
₹-50 Cr
₹-50 Cr
₹-52 Cr
₹-52 Cr
₹-49 Cr
₹-49 Cr
₹-59 Cr
₹-59 Cr
₹-38 Cr
₹-38 Cr
₹-62 Cr
₹-62 Cr
₹-13 Cr
₹-13 Cr
₹-53 Cr
—
Fermenta Biotech Ltd · FERMENTA⚠ unverified
₹187 Cr
₹187 Cr
₹213 Cr
—
—
—
₹160 Cr
₹159 Cr
₹117 Cr
₹117 Cr
₹79 Cr
₹79 Cr
₹88 Cr
₹88 Cr
₹44 Cr
₹44 Cr
₹60 Cr
₹60 Cr
₹80 Cr
—
Gujarat Themis Biosyn Ltd · GUJTHEM
₹-22 Cr
₹-22 Cr
₹-21 Cr
₹-23 Cr
₹-62 Cr
₹-62 Cr
₹-9 Cr
₹-9 Cr
₹-3 Cr
₹-3 Cr
₹-11 Cr
₹-12 Cr
₹-15 Cr
₹-15 Cr
₹18 Cr
₹17 Cr
₹61 Cr
₹61 Cr
₹156 Cr
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
₹956 Cr
₹956 Cr
₹932 Cr
₹932 Cr
₹902 Cr
₹902 Cr
₹844 Cr
₹844 Cr
₹789 Cr
₹789 Cr
₹-277 Cr
₹-415 Cr
₹-422 Cr
₹-422 Cr
₹-426 Cr
₹-426 Cr
₹-397 Cr
₹-397 Cr
₹-421 Cr
—
Innova Captab Ltd · INNOVACAP
—
—
₹198 Cr
₹198 Cr
—
—
₹230 Cr
₹371 Cr
₹460 Cr
₹460 Cr
₹161 Cr
₹161 Cr
₹243 Cr
₹243 Cr
₹273 Cr
₹273 Cr
₹278 Cr
₹278 Cr
₹276 Cr
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
₹-47 Cr
₹-47 Cr
—
—
₹-42 Cr
₹-42 Cr
₹-109 Cr
₹-109 Cr
₹-103 Cr
₹-103 Cr
₹-139 Cr
₹-139 Cr
₹-68 Cr
₹-68 Cr
₹-120 Cr
₹-120 Cr
₹-150 Cr
₹-150 Cr
₹-98 Cr
—
Kopran Ltd · KOPRAN⚠ unverified
₹77 Cr
₹77 Cr
₹69 Cr
₹69 Cr
₹74 Cr
₹74 Cr
₹68 Cr
₹68 Cr
₹86 Cr
₹86 Cr
₹91 Cr
₹85 Cr
₹116 Cr
₹116 Cr
₹129 Cr
₹122 Cr
₹120 Cr
₹120 Cr
₹146 Cr
—
Orchid Pharma Ltd · ORCHPHARMA
₹280 Cr
₹280 Cr
₹264 Cr
₹264 Cr
₹326 Cr
₹326 Cr
₹304 Cr
₹304 Cr
₹97 Cr
₹97 Cr
₹131 Cr
₹131 Cr
₹-79 Cr
₹-79 Cr
₹154 Cr
₹-5 Cr
₹133 Cr
₹133 Cr
₹280 Cr
—
Themis Medicare Ltd · THEMISMED⚠ unverified
₹41 Cr
₹41 Cr
₹60 Cr
₹54 Cr
₹58 Cr
₹58 Cr
₹79 Cr
₹73 Cr
₹73 Cr
₹73 Cr
₹86 Cr
₹86 Cr
₹63 Cr
₹63 Cr
₹76 Cr
₹70 Cr
₹83 Cr
₹83 Cr
₹91 Cr
—
Wanbury Ltd · WANBURY⚠ unverified
₹112 Cr
₹112 Cr
₹58 Cr
₹49 Cr
₹61 Cr
₹61 Cr
₹77 Cr
₹64 Cr
₹102 Cr
₹102 Cr
₹113 Cr
₹110 Cr
₹169 Cr
₹169 Cr
₹174 Cr
₹164 Cr
₹186 Cr
₹186 Cr
₹216 Cr
—
06 · compare level, then change
Return On Capital Employed
Wanbury Ltd has the highest ROCE among the 14 Pharma - API companies compared here, at 36.6%. Jagsonpal Pharmaceuticals Ltd is next at 22.7%. Senores Pharmaceuticals Ltd has the highest ROCE change at +4 percentage points, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Wanbury Ltd leads ROCE at 36.6%, 13.9 percentage points above Jagsonpal Pharmaceuticals Ltd. Senores Pharmaceuticals Ltd has the strongest latest improvement at +4 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderWanbury Ltd · 36.6%
Gap61.2% versus #2 · Jagsonpal Pharmaceuticals Ltd
Persistence1/8 recent comparable periods
Coverage14/14 companies · 179 observations
Investor read: Wanbury Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Wanbury Ltd WANBURY⚠ unverified37%
2Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified23%
3Fermenta Biotech Ltd FERMENTA⚠ unverified21%
4Beta Drugs Ltd BETA19%
5Gujarat Themis Biosyn Ltd GUJTHEM18%
ROCE changefastest improvers
1Senores Pharmaceuticals Ltd SENORES+4.0 pp
2Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified+3.5 pp
3Wanbury Ltd WANBURY⚠ unverified+2.4 pp
4Innova Captab Ltd INNOVACAP+0.4 pp
5Kopran Ltd KOPRAN⚠ unverified+0.1 pp
Return on capital · company comparison
14/14 level · 14/14 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
Withheld from this chart: Senores Pharmaceuticals Ltd (SENORES) — its two data sources disagree by up to 13% on reported income across 10 comparable periods, so its derived ratios are withheld; Beta Drugs Ltd (BETA) — its two data sources disagree by up to 50% on reported income across 11 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Wanbury Ltd WANBURY⚠ unverified | 29% | +2.4 pp | Mar 2026 |
| Fermenta Biotech Ltd FERMENTA⚠ unverified | 18% | −4.7 pp | Mar 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified | 17% | −0.1 pp | Mar 2026 |
| Gujarat Themis Biosyn Ltd GUJTHEM | 15% | −8.1 pp | Mar 2026 |
| Innova Captab Ltd INNOVACAP | 14% | +0.4 pp | Mar 2026 |
| Anuh Pharma Ltd ANUHPHR⚠ unverified | 13% | −3.3 pp | Mar 2026 |
| Aarti Drugs Ltd AARTIDRUGS | 13% | −0.4 pp | Mar 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | 12% | −5.1 pp | Mar 2026 |
| Kopran Ltd KOPRAN⚠ unverified | 11% | +0.1 pp | Mar 2026 |
| Orchid Pharma Ltd ORCHPHARMA | 0.3% | −5.6 pp | Mar 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified | -0.1% | +3.5 pp | Mar 2026 |
| Themis Medicare Ltd THEMISMED⚠ unverified | -2.3% | −11.4 pp | Mar 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Aarti Drugs Ltd · AARTIDRUGS
26%
—
23%
—
21%
—
17%
—
18%
20%
16%
16%
14%
15%
13%
15%
14%
14%
13%
—
Aarti Pharmalabs Ltd · AARTIPHARM
-7.3%
5.6%
11%
—
—
18%
17%
—
16%
17%
17%
19%
16%
19%
17%
19%
14%
14%
12%
—
Anuh Pharma Ltd · ANUHPHR⚠ unverified
8.9%
—
17%
—
18%
—
18%
—
20%
29%
23%
28%
21%
22%
17%
19%
15%
18%
13%
—
Fermenta Biotech Ltd · FERMENTA⚠ unverified
10%
—
7.2%
—
—
—
-2.3%
—
-4.0%
1.8%
0.8%
-0.7%
7.1%
18%
23%
34%
30%
29%
18%
—
Gujarat Themis Biosyn Ltd · GUJTHEM
54%
—
54%
—
51%
—
48%
—
36%
47%
37%
42%
30%
34%
23%
24%
19%
23%
15%
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
9.0%
—
6.3%
—
5.4%
—
13%
—
14%
13%
22%
51%
10%
43%
-3.6%
19%
-2.3%
21%
-0.1%
—
Innova Captab Ltd · INNOVACAP
—
—
6.1%
—
—
—
26%
17%
16%
26%
14%
19%
14%
18%
13%
16%
13%
16%
14%
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
24%
—
18%
—
17%
—
20%
—
17%
21%
11%
15%
14%
34%
17%
35%
17%
23%
17%
—
Kopran Ltd · KOPRAN⚠ unverified
22%
—
17%
—
16%
—
9.6%
—
9.2%
13%
13%
18%
13%
15%
11%
11%
7.8%
6.4%
11%
—
Orchid Pharma Ltd · ORCHPHARMA
-6.2%
—
-3.5%
—
-1.3%
—
—
—
2.8%
13%
6.0%
12%
6.9%
9.2%
5.9%
7.0%
2.1%
2.2%
0.3%
—
Themis Medicare Ltd · THEMISMED⚠ unverified
28%
—
27%
—
18%
—
15%
—
12%
17%
9.5%
18%
12%
16%
9.1%
1.0%
-5.0%
-1.8%
-2.3%
—
Wanbury Ltd · WANBURY⚠ unverified
-92%
—
130%
—
-84%
—
146%
174%
46%
94%
45%
116%
34%
59%
27%
43%
31%
42%
29%
—
ROCE change · reported quarter history
Aarti Drugs Ltd · AARTIDRUGS
—
—
—
—
−4.9 pp
—
−5.4 pp
—
−2.5 pp
—
−1.1 pp
—
−3.8 pp
−4.4 pp
−2.9 pp
−1.0 pp
−0.5 pp
−1.1 pp
−0.4 pp
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
+12.8 pp
+5.7 pp
—
—
−1.7 pp
−0.4 pp
—
0.0 pp
+2.5 pp
+0.2 pp
−0.1 pp
−1.2 pp
−5.1 pp
−5.1 pp
—
Anuh Pharma Ltd · ANUHPHR⚠ unverified
—
—
—
—
+9.5 pp
—
+1.0 pp
—
+1.6 pp
—
+4.9 pp
—
+0.6 pp
−7.0 pp
−6.1 pp
−8.9 pp
−6.0 pp
−4.6 pp
−3.3 pp
—
Fermenta Biotech Ltd · FERMENTA⚠ unverified
—
—
—
—
—
—
−9.5 pp
—
—
—
+3.1 pp
—
+11.1 pp
+16.4 pp
+21.7 pp
+34.4 pp
+22.6 pp
+10.7 pp
−4.7 pp
—
Gujarat Themis Biosyn Ltd · GUJTHEM
—
—
—
—
−3.1 pp
—
−6.1 pp
—
−14.9 pp
—
−10.9 pp
—
−5.8 pp
−13.0 pp
−13.8 pp
−17.3 pp
−11.3 pp
−11.4 pp
−8.1 pp
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
—
—
—
—
−3.6 pp
—
+6.2 pp
—
+8.2 pp
—
+9.5 pp
—
−3.3 pp
+29.6 pp
−25.6 pp
−31.9 pp
−12.6 pp
−22.2 pp
+3.5 pp
—
Innova Captab Ltd · INNOVACAP
—
—
—
—
—
—
+19.5 pp
—
—
—
−12.1 pp
+1.6 pp
−1.9 pp
−7.8 pp
−0.3 pp
−2.7 pp
−1.5 pp
−2.3 pp
+0.4 pp
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
—
—
—
—
−7.6 pp
—
+2.3 pp
—
+0.3 pp
—
−8.9 pp
—
−3.3 pp
+13.5 pp
+6.1 pp
+19.5 pp
+3.7 pp
−10.8 pp
−0.1 pp
—
Kopran Ltd · KOPRAN⚠ unverified
—
—
—
—
−5.4 pp
—
−7.1 pp
—
−7.0 pp
—
+3.4 pp
—
+4.0 pp
+1.4 pp
−2.4 pp
−6.7 pp
−5.4 pp
−8.1 pp
+0.1 pp
—
Orchid Pharma Ltd · ORCHPHARMA
—
—
—
—
+4.9 pp
—
—
—
+4.1 pp
—
—
—
+4.1 pp
−4.2 pp
−0.1 pp
−4.5 pp
−4.8 pp
−7.0 pp
−5.6 pp
—
Themis Medicare Ltd · THEMISMED⚠ unverified
—
—
—
—
−9.8 pp
—
−11.9 pp
—
−6.3 pp
—
−5.7 pp
—
−0.2 pp
−1.0 pp
−0.4 pp
−17.1 pp
−16.9 pp
−18.2 pp
−11.4 pp
—
Wanbury Ltd · WANBURY⚠ unverified
—
—
—
—
+7.4 pp
—
+16.1 pp
—
+129.8 pp
—
−101.3 pp
−58.1 pp
−12.1 pp
−35.3 pp
−18.0 pp
−73.5 pp
−3.1 pp
−16.2 pp
+2.4 pp
—
07 · compare level, then change
Valuation Against Growth & Quality
Innova Captab Ltd has the lowest Guarded PEG among the 14 Pharma - API companies compared here, at 1.01×. Aarti Drugs Ltd is next at 2.4×. Aarti Drugs Ltd has the lowest P/E at 18.9×, so level and change sit with different companies. 5 of 14 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Innova Captab Ltd has the lowest comparable Guarded PEG at 1.01×, 57.9% below Aarti Drugs Ltd. Only 5 of 14 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderInnova Captab Ltd · 1.01×
Gap57.9% versus #2 · Aarti Drugs Ltd
Persistence0/8 recent comparable periods
Coverage5/14 companies · 34 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.
Guarded PEGlowest PEG
1Innova Captab Ltd INNOVACAP1.0
2Aarti Drugs Ltd AARTIDRUGS2.4
3Gujarat Themis Biosyn Ltd GUJTHEM2.8
4Orchid Pharma Ltd ORCHPHARMA4.1
5Aarti Pharmalabs Ltd AARTIPHARM5.5
P/Elowest P/E
1Aarti Drugs Ltd AARTIDRUGS18.9
2Fermenta Biotech Ltd FERMENTA⚠ unverified20.2
3Anuh Pharma Ltd ANUHPHR⚠ unverified21.8
4Wanbury Ltd WANBURY⚠ unverified27.0
5Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified32.7
Valuation · company comparison
5/14 level · 14/14 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Guarded PEG | P/E | Reported |
|---|---|---|---|
| Aarti Pharmalabs Ltd AARTIPHARM | 5.5 | 25.6 | Mar 2026 |
| Orchid Pharma Ltd ORCHPHARMA | 4.1 | 98.1 | Mar 2026 |
| Gujarat Themis Biosyn Ltd GUJTHEM | 2.8 | 57.4 | Mar 2026 |
| Aarti Drugs Ltd AARTIDRUGS | 2.4 | 14.9 | Mar 2026 |
| Innova Captab Ltd INNOVACAP | 1.0 | 29.0 | Mar 2026 |
| Senores Pharmaceuticals Ltd SENORES | — | 35.7 | Mar 2026 |
| Beta Drugs Ltd BETA | — | 51.2 | Jun 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified | — | 20.0 | Mar 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified | — | 28.9 | Mar 2026 |
| Fermenta Biotech Ltd FERMENTA⚠ unverified | — | 11.4 | Mar 2026 |
| Wanbury Ltd WANBURY⚠ unverified | — | 17.6 | Mar 2026 |
| Themis Medicare Ltd THEMISMED⚠ unverified | — | 530.4 | Mar 2026 |
| Kopran Ltd KOPRAN⚠ unverified | — | 14.2 | Mar 2026 |
| Anuh Pharma Ltd ANUHPHR⚠ unverified | — | 16.8 | Mar 2026 |
Full 20-quarter history · every available company
Guarded PEG · reported quarter history
Aarti Drugs Ltd · AARTIDRUGS
1.1
—
—
—
—
—
—
—
—
—
—
—
—
—
0.6
—
3.2
2.4
—
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
—
0.3
—
—
2.3
0.4
1.4
1.5
1.3
1.0
1.1
1.5
5.5
—
—
Gujarat Themis Biosyn Ltd · GUJTHEM
0.7
2.7
—
0.4
0.7
0.6
0.9
—
1.3
—
1.5
—
—
—
—
—
2.8
—
—
—
Innova Captab Ltd · INNOVACAP
—
—
—
—
—
—
—
—
—
5.2
0.8
0.7
1.4
1.5
—
1.5
2.2
1.4
1.0
—
Orchid Pharma Ltd · ORCHPHARMA
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1.8
4.1
—
—
—
—
P/E · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
23.4
24.0
20.2
17.7
22.7
22.8
18.9
25.9
28.0
25.1
22.2
27.1
30.1
27.1
20.5
24.3
25.5
22.6
14.9
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
—
12.9
17.4
21.6
24.1
20.3
25.5
24.8
26.9
27.2
28.6
28.0
28.1
25.6
—
Beta Drugs Ltd · BETA
36.1
—
28.5
—
29.8
—
20.9
—
31.8
—
38.6
—
44.2
54.7
52.8
39.2
40.0
34.7
27.3
51.2
Fermenta Biotech Ltd · FERMENTA⚠ unverified
18.7
25.9
42.5
37.2
36.9
—
—
-8.4
—
-24.0
—
—
105.3
128.9
22.7
12.4
8.9
9.4
11.4
—
Gujarat Themis Biosyn Ltd · GUJTHEM
23.3
17.3
15.8
13.7
19.0
21.1
17.8
19.9
25.7
36.0
52.4
57.6
73.4
62.9
58.3
78.0
97.4
100.3
57.4
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
34.0
15.7
12.9
11.4
-1,632.7
36.4
28.9
15.4
17.5
16.6
20.6
3.7
4.1
3.9
3.7
4.8
27.6
20.2
20.0
—
Innova Captab Ltd · INNOVACAP
—
—
—
—
—
—
—
—
—
39.2
32.5
28.5
40.0
52.3
39.5
38.4
37.3
32.6
29.0
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
18.5
19.6
31.6
40.2
55.2
46.7
32.6
34.7
35.1
35.9
29.6
39.5
47.9
63.2
39.5
36.8
33.5
29.9
28.9
—
Orchid Pharma Ltd · ORCHPHARMA
-66.1
—
—
—
—
-76.6
—
147.0
59.5
50.3
57.7
63.1
64.8
77.2
35.7
36.0
42.9
74.0
98.1
—
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
—
—
—
—
—
—
—
55.1
55.3
39.7
44.0
43.5
35.7
—
Themis Medicare Ltd · THEMISMED⚠ unverified
15.8
12.3
12.1
9.2
15.9
21.6
18.6
22.0
28.8
38.4
44.4
44.3
51.9
45.9
29.3
40.0
36.1
-53.3
530.4
—
Wanbury Ltd · WANBURY⚠ unverified
—
-27.0
3.4
40.3
46.8
—
-11.7
117.0
107.4
41.6
19.9
16.6
34.2
33.3
41.4
30.6
18.9
17.9
17.6
—
08 · compare level, then change
Enterprise Value & Book Value
Fermenta Biotech Ltd has the lowest EV/EBITDA among the 14 Pharma - API companies compared here, at 7.7×. Kopran Ltd is next at 8.7×. Ind-Swift Laboratories Ltd has the lowest P/BV at 1.43×, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Fermenta Biotech Ltd leads ev/ebitda at 7.7×; Ind-Swift Laboratories Ltd leads p/bv at 1.43×.
LeaderFermenta Biotech Ltd · 7.7×
Gap11.5% versus #2 · Kopran Ltd
Persistence0/8 recent comparable periods
Coverage14/14 companies · 232 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.
EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.
EV/EBITDAlowest EV/EBITDA
1Fermenta Biotech Ltd FERMENTA⚠ unverified7.7
2Kopran Ltd KOPRAN⚠ unverified8.7
3Anuh Pharma Ltd ANUHPHR⚠ unverified10.4
4Wanbury Ltd WANBURY⚠ unverified10.5
5Aarti Drugs Ltd AARTIDRUGS11.6
P/BVlowest P/BV
1Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified1.4
2Kopran Ltd KOPRAN⚠ unverified1.8
3Anuh Pharma Ltd ANUHPHR⚠ unverified2.3
4Aarti Drugs Ltd AARTIDRUGS2.4
5Themis Medicare Ltd THEMISMED⚠ unverified2.5
Enterprise and book valuation · company comparison
14/14 level · 14/14 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | EV/EBITDA | P/BV | Reported |
|---|---|---|---|
| Themis Medicare Ltd THEMISMED⚠ unverified | 3,822.5 | 1.7 | Mar 2026 |
| Gujarat Themis Biosyn Ltd GUJTHEM | 37.4 | 10.4 | Mar 2026 |
| Orchid Pharma Ltd ORCHPHARMA | 36.2 | 2.0 | Mar 2026 |
| Beta Drugs Ltd BETA | 25.4 | 8.7 | Jun 2026 |
| Senores Pharmaceuticals Ltd SENORES | 20.2 | 4.5 | Mar 2026 |
| Innova Captab Ltd INNOVACAP | 17.5 | 3.8 | Mar 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified | 16.2 | 4.9 | Mar 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | 14.6 | 2.7 | Mar 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified | 12.7 | 0.9 | Mar 2026 |
| Aarti Drugs Ltd AARTIDRUGS | 11.6 | 2.1 | Mar 2026 |
| Wanbury Ltd WANBURY⚠ unverified | 10.5 | 9.8 | Mar 2026 |
| Anuh Pharma Ltd ANUHPHR⚠ unverified | 10.4 | 2.1 | Mar 2026 |
| Kopran Ltd KOPRAN⚠ unverified | 8.7 | 1.1 | Mar 2026 |
| Fermenta Biotech Ltd FERMENTA⚠ unverified | 7.7 | 2.6 | Mar 2026 |
Full 20-quarter history · every available company
EV/EBITDA · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
15.5
16.0
13.5
11.7
15.0
14.8
12.1
15.7
17.2
15.5
13.9
16.3
17.4
16.0
12.6
14.4
16.0
14.3
11.6
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
—
13.2
17.3
12.8
13.9
11.7
14.7
14.4
15.7
15.8
17.0
16.7
16.4
14.6
—
Beta Drugs Ltd · BETA
17.1
—
15.0
—
17.0
—
12.1
—
18.1
—
21.9
—
26.1
32.3
31.2
22.0
22.5
18.2
13.7
25.4
Fermenta Biotech Ltd · FERMENTA⚠ unverified
10.6
12.5
13.0
10.9
16.0
18.5
20.4
23.9
21.2
51.2
11.5
16.5
32.1
18.5
9.8
8.5
6.2
6.7
7.7
—
Gujarat Themis Biosyn Ltd · GUJTHEM
15.8
12.0
11.0
9.2
13.3
14.8
12.6
14.2
18.3
25.6
37.1
40.9
51.7
43.9
40.4
53.4
65.7
67.7
37.4
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
6.5
6.3
6.1
5.6
5.1
5.3
5.1
5.5
5.1
5.3
5.3
4.5
1.2
0.9
0.5
1.5
16.8
8.6
12.7
—
Innova Captab Ltd · INNOVACAP
—
—
—
—
—
—
—
—
—
29.5
25.1
18.4
25.6
34.4
27.6
25.6
24.2
20.2
17.5
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
11.4
12.4
20.4
25.1
34.8
31.0
22.2
24.2
23.0
23.2
49.3
24.2
28.7
40.1
25.9
22.3
20.3
17.6
16.2
—
Orchid Pharma Ltd · ORCHPHARMA
92.1
108.1
38.7
27.7
22.5
21.8
20.5
27.1
26.8
31.0
38.5
43.1
45.2
55.8
24.9
23.9
28.1
39.3
36.2
—
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
—
—
—
—
—
—
—
64.5
64.7
26.9
25.1
24.8
20.2
—
Themis Medicare Ltd · THEMISMED⚠ unverified
10.7
8.5
8.2
6.5
10.5
13.8
11.9
14.1
18.5
23.9
27.1
26.7
32.1
28.8
17.8
21.3
88.5
—
3,822.5
—
Wanbury Ltd · WANBURY⚠ unverified
21.2
13.6
17.9
10.5
9.5
8.0
7.8
10.0
7.7
10.5
8.8
8.2
14.6
14.6
13.9
13.1
11.1
10.6
10.5
—
P/BV · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Aarti Drugs Ltd · AARTIDRUGS
6.3
5.4
4.3
4.0
3.9
3.8
3.0
4.2
4.2
3.7
3.3
3.9
3.7
3.2
2.4
3.2
3.1
2.6
2.1
—
Aarti Pharmalabs Ltd · AARTIPHARM
—
—
—
—
—
—
1.6
2.2
2.7
2.8
2.4
3.5
3.2
3.3
3.7
4.4
3.8
3.3
2.7
—
Beta Drugs Ltd · BETA
6.2
—
6.5
—
6.9
—
6.5
—
8.0
—
8.4
—
10.3
11.0
10.6
11.4
9.3
7.1
5.3
8.7
Fermenta Biotech Ltd · FERMENTA⚠ unverified
2.2
2.3
1.7
1.6
1.7
1.4
0.8
1.1
1.5
1.7
1.6
1.6
3.1
3.8
2.8
3.3
2.5
2.7
2.6
—
Gujarat Themis Biosyn Ltd · GUJTHEM
12.5
7.2
6.5
8.5
6.9
8.4
9.7
11.2
10.0
10.5
16.2
16.9
20.0
14.8
13.7
18.6
17.5
18.3
10.4
—
Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified
0.6
0.7
0.6
0.6
0.5
0.6
0.5
0.8
0.8
0.9
0.9
1.1
0.8
0.6
0.5
0.7
0.6
0.6
0.9
—
Innova Captab Ltd · INNOVACAP
—
—
—
—
—
—
—
—
—
8.0
6.6
3.5
5.3
6.9
5.6
5.9
5.0
4.0
3.8
—
Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified
3.2
3.7
6.0
6.3
6.8
7.1
5.7
7.5
6.9
6.0
4.3
5.6
5.8
8.6
7.3
7.8
6.0
5.2
4.9
—
Orchid Pharma Ltd · ORCHPHARMA
2.6
2.4
1.7
1.8
2.1
2.4
2.4
3.1
3.1
3.3
4.8
6.7
6.2
7.5
3.2
3.1
2.9
3.0
2.0
—
Senores Pharmaceuticals Ltd · SENORES
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
3.4
4.1
4.7
4.5
—
Themis Medicare Ltd · THEMISMED⚠ unverified
4.3
3.3
3.2
3.1
3.0
3.9
3.8
4.3
4.9
5.4
5.5
5.7
6.9
5.9
3.3
3.2
3.0
2.5
1.7
—
Wanbury Ltd · WANBURY⚠ unverified
-1.4
-2.5
-2.7
-1.1
-6.8
-5.1
-5.2
-7.7
-9.8
-13.2
17.1
18.3
23.2
24.7
13.0
15.5
8.3
7.4
9.8
—
09 · let price answer last
Market action
Senores Pharmaceuticals Ltd has the strongest one-year price move in Pharma - API at +125.1%. Ind-Swift Laboratories Ltd leads on Mansfield relative strength against NIFTY at +80.6%. 11 of 14 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-17.
Every price line is indexed to 100 over the chosen window. Mansfield relative strength compares a price ratio with its own 52-week average; zero separates leadership from lagging.
Price and relative strength
Price is rebased to 100 inside the selected window. Pair ratio rebases each selected company against one chosen denominator.
Before the conclusion · check the blind spots
What can make this comparison misleading?
This Pharma - API comparison names 7 specific ways its own evidence can mislead, all listed below. All 14 companies here report on comparable dates, so no rank carries a stale marker. 7 draw at least one figure from a second feed with too little overlap to cross-check. 2 have second-feed figures withheld because the two sources disagree.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 7 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
- 2 companies are missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
- Thin comparisons: Capital expenditure have fewer than three usable current readings.
10 · the complete set
Which companies are included?
All 14 companies in the canonical Pharma - API membership are listed below, largest market value first — nothing is silently dropped, even where a company reports too little to rank. The charts above default to a selective view; this register is the complete set, with each company's own latest reporting date beside it.
AHEAD means the company is beating the index by 5% or more over three months. LAGGING, FUNDAMENTALS UP means it is 20% or more behind over a year while its trailing twelve-month earnings grew 20% or more. Both rules are fixed and applied the same way in every sector.
| Company | Market value | Price | Priced to | Latest fundamentals | Source standing |
|---|---|---|---|---|---|
| Senores Pharmaceuticals Ltd SENORESAHEAD24/26 WEEKS | ₹6.4K Cr | ₹1,388 | 2026-07-19 | Mar 2026 | Second feed withheld |
| Aarti Pharmalabs Ltd AARTIPHARM | ₹6.1K Cr | ₹674 | 2026-07-19 | Mar 2026 | Cross-checked |
| Innova Captab Ltd INNOVACAPAHEAD21/26 WEEKS | ₹5.4K Cr | ₹950 | 2026-07-19 | Mar 2026 | Cross-checked |
| Orchid Pharma Ltd ORCHPHARMAAHEAD | ₹5.0K Cr | ₹989 | 2026-07-19 | Mar 2026 | Cross-checked |
| Gujarat Themis Biosyn Ltd GUJTHEM | ₹3.9K Cr | ₹360 | 2026-07-19 | Mar 2026 | Cross-checked |
| Aarti Drugs Ltd AARTIDRUGSAHEAD | ₹3.7K Cr | ₹404 | 2026-07-19 | Mar 2026 | Cross-checked |
| Beta Drugs Ltd BETAAHEAD | ₹2.4K Cr | ₹2,316 | 2026-07-19 | Jun 2026 | Second feed withheld |
| Ind-Swift Laboratories Ltd INDSWFTLABAHEAD25/26 WEEKS⚠ unverified | ₹2.0K Cr | ₹227 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARMAHEAD19/26 WEEKS⚠ unverified | ₹1.5K Cr | ₹222 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| Fermenta Biotech Ltd FERMENTA⚠ unverified | ₹1.3K Cr | ₹432 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| Wanbury Ltd WANBURYAHEAD23/26 WEEKS⚠ unverified | ₹1.2K Cr | ₹332 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| Themis Medicare Ltd THEMISMEDAHEAD⚠ unverified | ₹1.0K Cr | ₹110 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| Kopran Ltd KOPRANAHEAD19/26 WEEKS⚠ unverified | ₹960 Cr | ₹199 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| Anuh Pharma Ltd ANUHPHR⚠ unverified | ₹792 Cr | ₹79.1 | 2026-07-19 | Mar 2026 | Includes unverified figures |
How each company's sources stand: 7 of 14 companies draw at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear. 2 of 14 companies have a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Senores Pharmaceuticals Ltd (SENORES) — its two data sources disagree by up to 13% on reported income across 10 comparable periods, so its derived ratios are withheld; Beta Drugs Ltd (BETA) — its two data sources disagree by up to 50% on reported income across 11 comparable periods, so its derived ratios are withheld.
Evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 14 Pharma - API companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-07-24. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-07-24 · weekly price and relative-strength history
Derived metricsGrowth, changes, CAPEX intensity, net debt, guarded PEG and P/BV÷ROE are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing5 cross-checked · 7 unverified · 2 withheld, of 14 graded companies.
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from. Every company's standing is listed in the register above.
Questions investors ask · short, speakable answers
Pharma - API company comparison FAQs
These 18 answers restate the Pharma - API comparison above in question form. Every one is computed from the same 14 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-07-24. Nothing here is estimated, and none of it is a recommendation.
What is the Nifty Pharma - API index?
The Nifty Pharma - API index tracks India's listed Pharma - API companies as a single basket. This page follows the same 14 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Pharma - API sector rather than to its largest constituent. Figures are as of Jun 2026.
Which are the best Pharma - API stocks in India?
Ranked by this page's four-factor score, Senores Pharmaceuticals Ltd places first among 14 listed Pharma - API companies, followed by Wanbury Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Pharma - API stocks are listed in India?
This comparison covers 14 listed Pharma - API companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Pharma - API company is the biggest?
Aarti Drugs Ltd is the largest, with trailing-twelve-month revenue of ₹2,566 crore, ahead of Aarti Pharmalabs Ltd at ₹1,819 crore. That covers 14 of 14 companies with comparable reporting through Mar 2026.
Which Pharma - API company is growing fastest?
Ind-Swift Laboratories Ltd has the fastest revenue growth at 100% year on year, across 14 of 14 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.
Which Pharma - API company has the best profit margins?
Gujarat Themis Biosyn Ltd has the highest operating margin at 44%, from 14 of 14 comparable companies. Ind-Swift Laboratories Ltd shows the biggest recent improvement, at +19 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Pharma - API company makes the most profit?
Aarti Drugs Ltd earns the most, at ₹195 crore of trailing-twelve-month net profit, from 14 of 14 comparable companies. Senores Pharmaceuticals Ltd has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Pharma - API company earns the highest return on capital?
Wanbury Ltd leads on return on capital employed at 36.6%, across 14 of 14 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Pharma - API stock is the cheapest?
On guarded PEG — where a LOWER number is cheaper — Innova Captab Ltd screens cheapest at 1.01×. Only 5 of 14 companies pass the comparability guard, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Which Pharma - API company has the strongest balance sheet?
Anuh Pharma Ltd carries the lowest comparable gross debt at ₹0 crore, from 14 of 14 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.
Which Pharma - API stock has the strongest price momentum?
Ind-Swift Laboratories Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Pharma - API company scores highest for research priority?
Senores Pharmaceuticals Ltd scores 73.3 out of 100 with 72% evidence confidence, from 30.8 points on growth and earnings, 15.2 on capital efficiency, 9.2 on valuation and 18.1 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Pharma - API companies does this comparison cover, and over what period?
It compares 14 listed companies over up to 20 reported quarters of fundamentals and 10 fiscal years of capital allocation, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Pharma - API sector?
The 14 Pharma - API companies on this page carry ₹41,621 crore of combined market value. Senores Pharmaceuticals Ltd is the largest at ₹6,390 crore, about 15% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-29.
What is the Pharma - API sector's P/E ratio?
The median price-to-earnings ratio across the 14 Pharma - API companies on this page is 38.8×, measured on the 14 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-07-29.
How is the Pharma - API sector performing?
11 of the 14 covered Pharma - API companies are beating NIFTY 500 on Mansfield relative strength. A 52-week sector-versus-index comparison is not available from the current market series for this sector, so it is not quoted. Readings are as of 2026-07-29.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.